Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 123

Sort by

Sort Order Select

Journal Articles

Single-cell multiomics reveals molecular identities and clonal dynamics of MRD progression in Myelodysplastic Syndromes after stem cell transplant

Yu-Hsiang Chen, Timothy Bi, Minhang Xu, Jaehyun Lee, Wesley Lu, Mengchuan Zhuang, Alejandro Marinos Velarde, Hui Yang, Gheath Alatrash, Gabriela Rondon, Elizabeth Shpall, Fatima Jelloul, Frances Cervoni-Curet, Celine Kerros, Priya Koppikar, Jeffrey Molldrem, Guillermo Garcia-Manero, Ankit Patel, Pavan Bachireddy

Blood (2025) 146 (Supplement 1): 674.

https://doi.org/10.1182/blood-2025-674

Published: 2025

Journal Articles

Clonal dynamics of FLT3-ITD positive acute myeloid leukemia following relapse after allogeneic stem cell transplantation

Blood (2025) 146 (Supplement 1): 592.

https://doi.org/10.1182/blood-2025-592

Published: 2025

Journal Articles

CRISPR-Cas9 screen-driven identification of metabolic vulnerabilities reveals synthetic lethality via synergistic targeting of mitochondrial energy pathways and lactate export in oxphos-dependent T-ALL

Blood (2025) 146 (Supplement 1): 1538.

https://doi.org/10.1182/blood-2025-1538

Published: 2025

Journal Articles

Mechanistic approach exploring combination agents to potentiate anti-leukemia activity of Hu8F4, a clinical stage T cell receptor mimic antibody

Anna Sergeeva, Hong He, Lisa St. John, Ling Yu, Rong Cai, Rolando Vedia, Celine Kerros, Kathryn Cox, Karen Clise-Dwyer, Gheath Alatrash, Jeffrey Molldrem

Blood (2025) 146 (Supplement 1): 1513.

https://doi.org/10.1182/blood-2025-1513

Published: 2025

Journal Articles

MMF is associated with higher non-relapse mortality and inferior survival in AML/MDS patients receiving peripheral blood matched allogeneic stem cell transplantation with post-transplant cyclophosphamide based gvhd prophylaxis

Blood (2025) 146 (Supplement 1): 5996.

https://doi.org/10.1182/blood-2025-5996

Published: 2025

Journal Articles

CD34+/TNC ratio predicts relapse in AML/MDS patients receiving peripheral blood matched allogeneic stem cell transplantation with post-transplant cyclophosphamide

Blood (2025) 146 (Supplement 1): 5994.

https://doi.org/10.1182/blood-2025-5994

Published: 2025

Journal Articles

Optimizing essential, complex hematologic care for patients living with disabilities

Blood (2025) 146 (Supplement 1): 4392.

https://doi.org/10.1182/blood-2025-4392

Published: 2025

Journal Articles

Myeloablative fractionated busulfan, fludarabine, cladribine, thiotepa, and venetoclax (Cladillac) conditioning for high-risk AML: A phase 2 trial

Blood (2025) 146 (Supplement 1): 378.

https://doi.org/10.1182/blood-2025-378

Published: 2025

Journal Articles

TCR-T cells targeting a public neoantigen produced by the SF3B1 K700E mutation kill SF3B1-mutant AML/MDS

Noah Tubo, Duncheng Wang, Qiuming He, Yibin Chen, Ho Ngai, Yanqing Huang, Celine Kerros, Xizeng Mao, Shoudan Liang, Hong He, Gheath Alatrash, Omar Abdel-Wahab, Priya Koppikar, Jeffrey Molldrem

Blood (2025) 146 (Supplement 1): 2363.

https://doi.org/10.1182/blood-2025-2363

Published: 2025

Journal Articles

Phase II trial of venetoclax in combination with azacitidine as maintenance therapy for high-risk acute leukemia following allogeneic stem cell transplantation

Betul Oran, Peter Thall, Gheath Alatrash, Jin Im, Jeremy Ramdial, Roland Bassett, Uday Popat, Partow Kebriaei, Portia Smallbone, Jessica Jewell, Richard Champlin, Elizabeth Shpall

Blood (2025) 146 (Supplement 1): 2511.

https://doi.org/10.1182/blood-2025-2511

Published: 2025

Journal Articles

A phase I study of the T-cell receptor-like antibody Hu8F4 in pts with advanced myeloid neoplasms

Blood (2025) 146 (Supplement 1): 1646.

https://doi.org/10.1182/blood-2025-1646

Published: 2025

Journal Articles

Allogeneic stem cell transplant for T-prolymphocytic leukemia: A single center analysis

Blood (2025) 146 (Supplement 1): 1869.

https://doi.org/10.1182/blood-2025-1869

Published: 2025

Journal Articles

Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa and Venetoclax (Cladillac) Conditioning Regimen for Very High-Risk AML/MDS: A Phase 2 Trial

Blood (2024) 144 (Supplement 1): 506.

https://doi.org/10.1182/blood-2024-203338

Published: 2024

Journal Articles

CBX250 Is a Novel Cathepsin G Peptide-HLA-Targeting T Cell Engager That Exhibits High Tumor Antigen Selectivity and Potent Antileukemic Activity In Vivo

Blood (2024) 144 (Supplement 1): 208.

https://doi.org/10.1182/blood-2024-201699

Published: 2024

Journal Articles

Cord-Derived Invariant Natural Killer T Cells As Novel Cell Therapy to Improve the Outcome of Hematopoietic Stem Cell Transplantation

Abel Trujillo-Ocampo, Maison Grefe, Pamella Borges, Jelita Clinton, Hong He, Dan Li, Ling Yu, Martiela Vaz de Freitas, Lisa St. John, Karen Clise-Dwyer, Gheath Alatrash, Dinler Amaral Antues, Qing Ma, Jeffrey J. Molldrem, Elizabeth J. Shpall, Jin S. Im

Blood (2024) 144 (Supplement 1): 4818.

https://doi.org/10.1182/blood-2024-210168

Published: 2024

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation Following CAR T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia

Natalie Rafaeli, David Marin, Celina Ledesma, Nitin Jain, Priti Tewari, Issa F. Khouri, Amanda L. Olson, Gheath Alatrash, Nicholas J. Short, Elias Jabbour, Katy Rezvani, Amin M. Alousi, Uday Popat, Richard E. Champlin, Elizabeth J. Shpall, Partow Kebriaei

Blood (2024) 144 (Supplement 1): 2810.

https://doi.org/10.1182/blood-2024-193954

Published: 2024

Journal Articles

Efficacy and Safety of Pembrolizumab Added to Azacitidine Plus Venetoclax for Patients with Acute Myeloid Leukemia: Results from an Investigator-Initiated, Multi-Center, CTEP-Sponsored Randomized, Phase II Trial (BLAST AML-2)

Blood (2024) 144 (Supplement 1): 736.

https://doi.org/10.1182/blood-2024-210370

Published: 2024

Journal Articles

Clonal Origin of Therapy-Related Myeloid Neoplasms after Autologous Stem Cell Transplant

Blood (2024) 144 (Supplement 1): 346.

https://doi.org/10.1182/blood-2024-208106

Published: 2024

Journal Articles

A Phase I Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with High Risk or Refractory/Relapsed Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation

Blood (2024) 144 (Supplement 1): 1047.

https://doi.org/10.1182/blood-2024-211343

Published: 2024

Journal Articles

Tagraxofusp Maintenance Post-Hematopoietic Stem Cell Transplantation Provides Long-Term Survival and Manageable Safety for a Patient with Blastic Plasmacytoid Dendritic Cell Neoplasm

Qaiser Bashir, Marina Y. Konopleva, Glorette Abueg, Jeremy Ramdial, Chitra Hosing, Samer A. Srour, Amin Alousi, Uday R. Popat, Yago Nieto, Gheath Alatrash, Richard E. Champlin, Elizabeth J. Shpall, Muzaffar H. Qazilbash, Naveen Pemmaraju

Blood (2023) 142 (Supplement 1): 7058.

https://doi.org/10.1182/blood-2023-178874

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Single-cell multiomics reveals molecular identities and clonal dynamics of MRD progression in Myelodysplastic Syndromes after stem cell transplant

Clonal dynamics of FLT3-ITD positive acute myeloid leukemia following relapse after allogeneic stem cell transplantation

CRISPR-Cas9 screen-driven identification of metabolic vulnerabilities reveals synthetic lethality via synergistic targeting of mitochondrial energy pathways and lactate export in oxphos-dependent T-ALL

Mechanistic approach exploring combination agents to potentiate anti-leukemia activity of Hu8F4, a clinical stage T cell receptor mimic antibody

MMF is associated with higher non-relapse mortality and inferior survival in AML/MDS patients receiving peripheral blood matched allogeneic stem cell transplantation with post-transplant cyclophosphamide based gvhd prophylaxis

CD34+/TNC ratio predicts relapse in AML/MDS patients receiving peripheral blood matched allogeneic stem cell transplantation with post-transplant cyclophosphamide

Optimizing essential, complex hematologic care for patients living with disabilities

Myeloablative fractionated busulfan, fludarabine, cladribine, thiotepa, and venetoclax (Cladillac) conditioning for high-risk AML: A phase 2 trial

TCR-T cells targeting a public neoantigen produced by the SF3B1 K700E mutation kill SF3B1-mutant AML/MDS

Phase II trial of venetoclax in combination with azacitidine as maintenance therapy for high-risk acute leukemia following allogeneic stem cell transplantation

A phase I study of the T-cell receptor-like antibody Hu8F4 in pts with advanced myeloid neoplasms

Allogeneic stem cell transplant for T-prolymphocytic leukemia: A single center analysis

Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa and Venetoclax (Cladillac) Conditioning Regimen for Very High-Risk AML/MDS: A Phase 2 Trial

CBX250 Is a Novel Cathepsin G Peptide-HLA-Targeting T Cell Engager That Exhibits High Tumor Antigen Selectivity and Potent Antileukemic Activity In Vivo

Cord-Derived Invariant Natural Killer T Cells As Novel Cell Therapy to Improve the Outcome of Hematopoietic Stem Cell Transplantation

Allogeneic Hematopoietic Stem Cell Transplantation Following CAR T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia

Efficacy and Safety of Pembrolizumab Added to Azacitidine Plus Venetoclax for Patients with Acute Myeloid Leukemia: Results from an Investigator-Initiated, Multi-Center, CTEP-Sponsored Randomized, Phase II Trial (BLAST AML-2)

Clonal Origin of Therapy-Related Myeloid Neoplasms after Autologous Stem Cell Transplant

A Phase I Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with High Risk or Refractory/Relapsed Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation

Tagraxofusp Maintenance Post-Hematopoietic Stem Cell Transplantation Provides Long-Term Survival and Manageable Safety for a Patient with Blastic Plasmacytoid Dendritic Cell Neoplasm

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only